Skip to content

A Novel Risk Prediction Model for Chronic Atrophic Gastritis Based onTCM Spleen Deficiency, Blood Stasis Syndromes, and Gastric Stem CellDynamics

Analysis of Lgr5 and TFF2 expression patterns in the gastric mucosa of patients with high-risk atrophic gastritis presenting with spleen deficiency and blood stasis syndrome, based on the Wnt/ß-catenin pathway

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2026001295
Enrollment
Unknown
Registered
2026-05-26
Start date
2023-03-24
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Atrophic Gastritis, Gastric Precancerous Lesion

Interventions

High-risk atrophic gastritis:None
Superficial Gastritis:None
Superficial gastritis with H. pylori infection:None
Low-risk atrophic gastritis:None

Sponsors

Xiyuan Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Outpatients and inpatients diagnosed via gastroscopy and histopathology as having simple superficial gastritis, superficial gastritis with H. pylori infection, or atrophic gastritis with or without intestinal metaplasia or dysplasia. (2) Patients whose Traditional Chinese Medicine (TCM) pattern differentiation corresponds to the 'spleen deficiency with blood stasis' syndrome. (3) Aged between 18 and 75 years. (4) Patients must be alert, articulate, able to read, and capable of communicating effectively with the investigators. (5) Patients must be willing to undergo immunohistochemical testing and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Those with a history of gastric ulcers, gastric polyps or gastric surgery. (2) Those taking NSAIDs on a long-term basis. (3) Those with concomitant severe cardiovascular or cerebrovascular disease, liver disease, kidney disease, haematological disorders or malignant tumours. (4) Those with suspected malignant gastric lesions, or a history of malignant gastrointestinal tumours or surgery. (5) Women who are planning to conceive, are pregnant or are breastfeeding.

Design outcomes

Primary

MeasureTime frame
Lgr5 TFF2 ß-catenin Cyclin D1 Ki67 Bax;Pathological diagnosis;

Secondary

MeasureTime frame
General Information;Risk factors for stomach cancer;Information on the Four Diagnostic Methods;Gastroscopic diagnosis;

Countries

China

Contacts

Public ContactPing WANG

Xiyuan Hospital, China Academy of Chinese Medical Sciences

celia_1224@163.com15838279252

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026